This is a StreetInsider.com Premium Only Page

Sarepta Therapeutics (SRPT) – StreetInsider.com Reports

Apr 4, 2024 04:14 PM Citi Issues 90-Day Upside Catalyst Watch on Sarepta Therapeutics (SRPT)

Apr 4, 2024 08:08 AM These 8 stocks are the latest additions to Mizuho's Top Picks list

Mar 1, 2024 07:46 AM Sarepta Therapeutics (SRPT) PT Raised to $167 at UBS

Feb 29, 2024 11:53 AM Sarepta Therapeutics (SRPT) PT Lowered to $156 at Deutsche Bank

Feb 29, 2024 07:49 AM Sarepta Therapeutics (SRPT) PT Lowered to $166 at Needham

Feb 29, 2024 06:14 AM Sarepta Therapeutics (SRPT) PT Raised to $157 at RBC Capital

Feb 29, 2024 03:43 AM Sarepta Therapeutics (SRPT) PT Raised to $185 at Barclays

Feb 28, 2024 04:15 PM Sarepta Therapeutics (SRPT) Tops Q4 EPS by 84c

Feb 20, 2024 08:55 AM Sarepta Therapeutics (SRPT) PT Raised to $160 at Morgan Stanley

Feb 20, 2024 06:21 AM Sarepta Therapeutics (SRPT) PT Raised to $170 at Baird

Feb 20, 2024 04:05 AM Sarepta Therapeutics (SRPT) PT Raised to $158 at Deutsche Bank

Feb 16, 2024 07:46 AM Sarepta stock jumps on FDA nod for ELEVIDYS gene therapy

Feb 16, 2024 07:22 AM Sarepta Therapeutics (SRPT) Climbs 20% After Announcing U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication

Feb 16, 2024 07:00 AM Sarepta Therapeutics (SRPT) Announces FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication

Feb 14, 2024 06:35 AM Sarepta Therapeutics (SRPT) PT Raised to $145 at Mizuho Securities

Feb 5, 2024 04:06 AM Sarepta Therapeutics (SRPT) PT Raised to $160 at Citi

Jan 31, 2024 10:59 AM BMO initiates coverage on Sarepta Therapeutics (SRPT) with Outperform rating

Jan 31, 2024 03:47 AM BMO Capital Starts Sarepta Therapeutics (SRPT) at Outperform, 'DMD's High Unmet Need Is All That Matters'

Jan 29, 2024 07:01 AM Sarepta Therapeutics (SRPT) Announces Positive Data from Part B of MOMENTUM Study

Jan 25, 2024 07:14 AM Sarepta Therapeutics (SRPT) PT Lowered to $151 at RBC Capital

Jan 22, 2024 08:13 AM Sarepta Therapeutics (SRPT) PT Raised to $177 at JPMorgan

Jan 9, 2024 09:23 AM Sarepta Therapeutics shares rally, Mizuho says confidence in label expansion 'remains unwavering'

Jan 8, 2024 11:55 AM Sarepta Therapeutics (SRPT) Reports Preliminary Fourth Quarter and Full-Year 2023 Net Product Revenue

Dec 22, 2023 08:01 AM Sarepta Therapeutics (SRPT) Submits Efficacy Supplement to Expand the ELEVIDYS Label to include DMD Patients without Restriction to Age or Ambulatory Status

Dec 21, 2023 06:26 AM Sarepta Therapeutics (SRPT) PT Raised to $103 at Guggenheim

Dec 20, 2023 04:03 AM Sarepta Therapeutics (SRPT) PT Lowered to $130 at Mizuho Securities

Dec 12, 2023 05:35 PM After-hours movers: Cal-Maine falls on bird flu, TE Connectivity gains on buyback

Dec 12, 2023 04:10 PM Citi Starts Sarepta Therapeutics (SRPT) at Buy, 'Optimistic Outlook as DMD Gene Therapy Goes in Front of FDA Again'

Dec 11, 2023 04:09 PM Deutsche Bank Starts Sarepta Therapeutics (SRPT) at Buy

Nov 20, 2023 04:06 PM Wedbush Starts Sarepta Therapeutics (SRPT) at Outperform

Nov 9, 2023 11:03 AM Sarepta Therapeutics (SRPT) 30-day option implied volatility near lower end of range as share price down 4%

Nov 6, 2023 11:00 AM Sarepta Therapeutics (SRPT) gains on insider buying following wipeout

Nov 2, 2023 07:54 AM Sarepta Therapeutics (SRPT) PT Raised to $115 at TD Cowen

Nov 2, 2023 07:26 AM Sarepta Therapeutics (SRPT) PT Raised to $93 at Needham & Company

Nov 2, 2023 06:33 AM Sarepta Therapeutics (SRPT) PT Raised to $80 at Cantor Fitzgerald

Nov 1, 2023 04:15 PM Sarepta Therapeutics (SRPT) Tops Q3 EPS by 76c

Oct 31, 2023 10:32 AM Sarepta Therapeutics (SRPT) call put ratio 1.5 calls to 1 put as share price down 42%

Oct 31, 2023 09:14 AM Sarepta Therapeutics (SRPT) PT Lowered to $164 at BofA Securities

Oct 31, 2023 08:34 AM Why Catalent (CTLT) is getting slaughtered today

Oct 31, 2023 08:11 AM Sarepta Therapeutics (SRPT) PT Lowered to $146 at Morgan Stanley

Oct 31, 2023 07:56 AM Sarepta Therapeutics crushed after EMBARK misses primary endpoint, prompting 2 downgrades

Oct 31, 2023 07:32 AM Sarepta Therapeutics (SRPT) option IV into the firm said its EMBARK readout missed its primary endpoint

Oct 31, 2023 07:22 AM Sarepta Therapeutics (SRPT) PT Lowered to $115 at JPMorgan

Oct 31, 2023 07:13 AM Sarepta Therapeutics (SRPT) Resumes Trading, Down 40%

Oct 31, 2023 07:03 AM Roche hits 5-year lows on disappointing study results, JPMorgan's bearish comments

Oct 31, 2023 06:54 AM Oppenheimer Downgrades Sarepta Therapeutics (SRPT) to Perform, seeks "greater clarity on FDA feedback, timelines for potential full approval, full safety dataset"

Oct 31, 2023 06:26 AM Sarepta Therapeutics (SRPT) PT Lowered to $136 at Baird

Oct 31, 2023 06:14 AM Sarepta Therapeutics (SRPT) PT Lowered to $148 at RBC Capital

Oct 31, 2023 05:43 AM Sarepta Therapeutics (SRPT) PT Lowered to $94 at Evercore ISI

Oct 31, 2023 03:11 AM Cantor Fitzgerald Downgrades Sarepta Therapeutics (SRPT) to Neutral